Latest news with #RebeccaMcLeod
Otago Daily Times
29-06-2025
- Climate
- Otago Daily Times
Climate strategy makes ‘lot of progress'
Dr Rebecca McLeod. Photo: ODT files In the six months since the Otago Regional Council adopted a climate strategy "a lot of progress has been made", principal strategy adviser Rebecca McLeod says. Further, Dr McLeod said two large pieces of work would soon come to councillors for their consideration. She presented councillors with the organisation's first "annual report" on the implementation and effectiveness of its climate strategy last week. "It's only actually been six months since the climate strategy was adopted in December last year, but we think quite a lot of progress has been made in a short time," Dr McLeod said. Climate change was a strong theme in the council's work, which "cuts across" all 18 of the council's strategic directions, she said. Significant progress had been made on an organisational emissions inventory, which was a "really foundational piece of work" for the council. That work is due to be presented to councillors before the end of the year and will provide a foundation for the council's yet to be developed emissions reduction plan. Secondly, Dr McLeod said a gaps analysis was planned for next year that would involve working with teams across the council, but also with other councils in the region, to look at "what we should be doing or could be doing more of or less of in order to meet the goals of the climate strategy". That work was due to take "a bit of time", but staff planned to present the analysis to councillors in the first half of next year. The gaps analysis would start to look at sequestration opportunities across the region "and then what the role is of the regional council in that space". "There's quite a bit of interesting work going on at the moment at the national government level where they're starting to look at whether they should be supporting a voluntary credit system for nature credits," Dr McLeod said. "And there's also work going on looking at whether coastal wetlands should be brought into the ETS [Emissions Trading Scheme]. "So that's actually quite good timing for us. "Hopefully, by the time we've finished the gaps analysis or got some way through the gaps analysis, the national direction on that will be quite clear." A statement from the council said that most of 53 actions in the council's climate strategy were "on track". Forty-three actions were on track, while four actions were "off track", those actions largely awaiting the outcome of central government policy reform, the statement said. Actions included in the strategy were those that would drive a reduction of the organisation's carbon emissions, several that would deliver better environmental monitoring and others that would lead to the region adapting to a changing climate, it said. — APL
Yahoo
06-06-2025
- Business
- Yahoo
Exploring Three High Growth Tech Stocks In The US Market
In the last week, the United States market has been flat, but it is up 11% over the past year with earnings expected to grow by 14% per annum over the next few years. In this context, identifying high growth tech stocks involves looking for companies that not only demonstrate strong innovation and scalability but also have solid financial health to capitalize on these favorable market conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ Travere Therapeutics 26.41% 64.47% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Alnylam Pharmaceuticals 23.64% 61.12% ★★★★★★ Ascendis Pharma 35.15% 60.20% ★★★★★★ Lumentum Holdings 22.53% 112.10% ★★★★★★ Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Scholar Rock Holding Corporation is a biopharmaceutical company dedicated to discovering, developing, and delivering medicines targeting serious diseases influenced by protein growth factor signaling, with a market cap of $3.25 billion. Operations: Scholar Rock Holding Corporation specializes in creating therapeutics for diseases impacted by protein growth factor signaling. The company operates within the biopharmaceutical sector, focusing on innovative drug development and delivery. Scholar Rock Holding's recent appointment of Rebecca McLeod as Chief Brand Officer ahead of the U.S. commercial launch of apitegromab signals a strategic push into new markets, underscoring its commitment to expanding its global footprint. This move, coupled with robust annualized revenue growth at 56.5% and an anticipated shift to profitability within three years, reflects a dynamic adaptation in response to evolving market demands in biotechnology. Moreover, the firm's R&D focus is evident from its significant investment in developing apitegromab, highlighted by promising results from the pivotal Phase 3 SAPPHIRE trial. These developments suggest Scholar Rock is strategically positioning itself at the forefront of innovation in treatments for spinal muscular atrophy, despite recent financial challenges indicated by a net loss increase to $74.72 million from $56.85 million year-over-year. Dive into the specifics of Scholar Rock Holding here with our thorough health report. Gain insights into Scholar Rock Holding's past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Atlassian Corporation, with a market cap of $55.37 billion, operates globally by designing, developing, licensing, and maintaining a variety of software products through its subsidiaries. Operations: Atlassian generates revenue primarily from its software and programming segment, amounting to $4.96 billion. The company's operations focus on designing, developing, and licensing a range of software products worldwide. Atlassian, amidst a challenging fiscal landscape marked by a net loss shift from $103.6 million to $232.78 million year-over-year, continues to demonstrate robust engagement within the tech community through multiple high-profile presentations across global conferences. Notably, the firm's commitment to innovation is underscored by its aggressive share repurchase strategy, having reacquired shares worth approximately $939.68 million since early 2023. This strategic financial maneuvering coincides with an expected surge in revenue growth, projected at 15.7% annually, which outpaces the broader U.S market forecast of 8.6%. Moreover, Atlassian's anticipated transition to profitability within three years highlights its potential resilience and adaptability in navigating software industry dynamics effectively. Take a closer look at Atlassian's potential here in our health report. Explore historical data to track Atlassian's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★★☆ Overview: HubSpot, Inc. offers a cloud-based customer relationship management platform for businesses across the Americas, Europe, and the Asia Pacific, with a market cap of approximately $31.61 billion. Operations: The company generates revenue primarily from its Internet Software & Services segment, totaling approximately $2.72 billion. HubSpot's strategic integration with AI, specifically the launch of a deep research connector with ChatGPT, marks a significant enhancement in CRM capabilities, directly impacting go-to-market teams across various departments. This innovation not only streamlines operations but also personalizes customer interactions by leveraging advanced analytics directly within the HubSpot platform. Financially, HubSpot is navigating through unprofitability with an ambitious outlook; its revenue is expected to climb by 14% annually, outperforming the U.S market projection of 8.6%. Moreover, with a robust forecast for earnings growth at 44% per year and R&D expenses strategically allocated to fuel these advancements, HubSpot is positioning itself as a formidable player in high-tech solutions despite current financial pressures. Click here and access our complete health analysis report to understand the dynamics of HubSpot. Assess HubSpot's past performance with our detailed historical performance reports. Gain an insight into the universe of 226 US High Growth Tech and AI Stocks by clicking here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SRRK TEAM and HUBS. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP CAMBRIDGE, Mass., June 02, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with SMA – along with establishing the global apitegromab brand strategy and market positioning for Europe, Asia-Pacific and Latin America. "Rebecca's unprecedented experience in building and leading U.S. operations at argenx to launch VYVGART® successfully is invaluable as Scholar Rock accelerates planning toward our anticipated initial launch in SMA this year," said R. Keith Woods, Chief Operating Officer of Scholar Rock. "Launching apitegromab in the U.S. is vital in bringing the potentially transformative benefits of apitegromab to patients with SMA. I am confident that under her leadership, we will deliver for the SMA community in the U.S. and around the world as we become a global leader in developing and delivering innovative therapies to treat patients with rare, severe and debilitating neuromuscular disorders." Ms. McLeod is a 25-year pharmaceutical and biotechnology industry veteran who joins Scholar Rock from argenx, where she led market access, distribution, patient services, medical affairs, operations, marketing and sales for the U.S. organization. Under her leadership, argenx has delivered one of the most successful biopharmaceutical franchise launches with VYVGART. Earlier, she served in several commercial leadership positions across sales, marketing and product management at Alexion Pharmaceuticals and Takeda Pharmaceuticals. "I am thrilled to join Scholar Rock at this pivotal time of scale and growth as we prepare to become a global commercial biotechnology company," said Ms. McLeod. "I'm honored to leverage my leadership experience over the past seven years in the neuromuscular rare disease space to now build and lead Scholar Rock's U.S. operations as we plan to deliver apitegromab for children and adults with SMA, while also rolling out our global apitegromab brand strategy." About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily, the company is named for the visual resemblance of a scholar rock to protein structures. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at and follow @ScholarRock and on LinkedIn. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. VYVGART® is a trademark of argenx. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, the timing and results of regulatory submissions, the therapeutic potential of apitegromab, its transition to a fully integrated global commercial enterprise and planned launch of apitegromab, the establishment of its global brand strategy and the anticipated impact of the leadership appointment described herein. The use of words such as "may," "might," "could," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether the results from the Phase 3 SAPPHIRE trial will be sufficient to support regulatory approval, that preclinical and clinical data, including the results from the Phase 2 or Phase 3 clinical trial of apitegromab, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials; and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and Scholar Rock's ability to continue as a going concern; as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. View source version on Contacts Scholar Rock: Investors & Media Rushmie NofsingerScholar Rockrnofsinger@ ir@ 857-259-5573 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
